# Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)

> **NCT06553768** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Mirum Pharmaceuticals, Inc.** · enrollment: 90 (estimated)

## Conditions studied

- Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)

## Interventions

- **DRUG:** Maralixibat
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06553768
- **Lead sponsor:** Mirum Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-10-14
- **Primary completion:** 2026-10
- **Final completion:** 2027-02
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06553768

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06553768, "Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06553768. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*